CLINICAL TRIALS PROFILE FOR PILOCARPINE HYDROCHLORIDE

505(b)(2) Clinical Trials for Pilocarpine Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT02935894 ↗	Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat	Completed	University of California, Davis	N/A	2016-11-28	The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation. Additionally, the investigators want to know whether the amount and small molecule content of the sweat is the same in an individual over time, and the same across individuals at a given time. Finally, the investigators want to know how consumption of over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory mediator content of sweat and how that compares to blood. This information will help to better understand the composition and behavior of sweat and assess its potential utility as a routine clinical tool in skin research.
OTC	NCT02935894 ↗	Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat	Completed	USDA, Western Human Nutrition Research Center	N/A	2016-11-28	The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation. Additionally, the investigators want to know whether the amount and small molecule content of the sweat is the same in an individual over time, and the same across individuals at a given time. Finally, the investigators want to know how consumption of over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory mediator content of sweat and how that compares to blood. This information will help to better understand the composition and behavior of sweat and assess its potential utility as a routine clinical tool in skin research.

All Clinical Trials for Pilocarpine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003139 ↗	Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1998-03-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer. PURPOSE: Randomized, double-blinded, phase III trial to study the effectiveness of pilocarpine in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer.
NCT00003139 ↗	Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer	Completed	Radiation Therapy Oncology Group	Phase 3	1998-03-01	RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as pilocarpine may protect normal cells from the side effects of radiation therapy. It is not yet known if pilocarpine may be effective in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer. PURPOSE: Randomized, double-blinded, phase III trial to study the effectiveness of pilocarpine in preventing mucositis and dry mouth in patients receiving radiation therapy for head and neck cancer.
NCT00003686 ↗	Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids	Terminated	NCIC Clinical Trials Group	Phase 3	1998-05-22	RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer therapy. It is not yet known whether pilocarpine is more effective than no further treatment for this condition. PURPOSE: Randomized phase III trial to determine the effectiveness of pilocarpine in treating patients who have dry mouth caused by opioids.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	CancerCare Manitoba	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Jewish General Hospital	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.
NCT00168181 ↗	Trial Comparing Oral Pilocarpine (Salagen) Versus Submandibular Salivary Gland Transfer Protocol, For the Prevention of Radiation (XRT) Induced Xerostomia in Head and Neck Cancer Patients	Completed	Newfoundland Cancer Treatment & Research Foundation	Phase 3	2002-04-01	This is a study to see whether the drug Salagen or salivary gland transfer is better for the prevention of dryness of the mouth in patients with head and neck cancer receiving radiation treatment.

Clinical Trial Conditions for Pilocarpine Hydrochloride

Condition Name

Condition Name for Pilocarpine Hydrochloride
Intervention	Trials
Presbyopia	12
Xerostomia	7
Dry Mouth	6
Glaucoma	5

Condition MeSH

Condition MeSH for Pilocarpine Hydrochloride
Intervention	Trials
Xerostomia	14
Presbyopia	13
Glaucoma	8
Glaucoma, Open-Angle	3

Clinical Trial Locations for Pilocarpine Hydrochloride

Trials by Country

Trials by Country for Pilocarpine Hydrochloride
Location	Trials
United States	117
Canada	11
China	3
Iran, Islamic Republic of	2
Germany	2

Trials by US State

Trials by US State for Pilocarpine Hydrochloride
Location	Trials
California	8
Texas	7
New York	7
Colorado	5
Ohio	5

Clinical Trial Progress for Pilocarpine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Pilocarpine Hydrochloride
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
Phase 4	6

Clinical Trial Status

Clinical Trial Status for Pilocarpine Hydrochloride
Clinical Trial Phase	Trials
Completed	26
Recruiting	13
Not yet recruiting	6

Clinical Trial Sponsors for Pilocarpine Hydrochloride

Sponsor Name

Sponsor Name for Pilocarpine Hydrochloride
Sponsor	Trials
Roxane Laboratories	4
National Cancer Institute (NCI)	3
Xuanwu Hospital, Beijing	2

Sponsor Type

Sponsor Type for Pilocarpine Hydrochloride
Sponsor	Trials
Other	61
Industry	20
NIH	4

Pilocarpine Hydrochloride: Clinical-Development Update, Market View, and Revenue Projection Framework

Last updated: April 28, 2026

What is pilocarpine hydrochloride and where does it compete?

Pilocarpine hydrochloride is a muscarinic (M3-preferring) secretagogue used to increase salivary and tear production in conditions marked by glandular hypofunction. In current practice, its commercial use is centered on:

• Xerostomia due to Sjögren’s syndrome (saliva stimulation)
• Dry eye disease due to Sjögren’s syndrome (tear stimulation)

Market structure is shaped by patent and off-patent generics. Most global supply is dominated by multiple ANDA/authorized generic entries, with pricing driven by generic competition in many geographies. R&D intensity for new clinical candidates is therefore typically concentrated in:

• Line extensions (different dosing regimens, formulations, or patient subsets)
• Alternative routes and delivery (less common, but higher unit economics when differentiated)
• Product lifecycle management (behavioral and adherence improvements through formulation)

What do the clinical-trial signals indicate?

A complete, current clinical-trials inventory requires a live registry pull (e.g., ClinicalTrials.gov). In the absence of a time-stamped trial list in the materials provided, a precise, trial-by-trial update cannot be produced without risking incorrect inclusion or omission.

What can be stated at the drug-class level:

• Pilocarpine is not a late-stage pipeline archetype in the way monoclonal antibodies or novel small molecules are.
• Development activity, where present, typically concentrates on formulation, delivery, adherence, and local-regimen optimization rather than new mechanisms.

What is the market baseline for pilocarpine hydrochloride?

A business-grade market view needs three hard inputs: (1) addressable patient counts, (2) current penetration by brand vs generic, and (3) pricing/discount levels by geography. Those data were not provided in the request materials, so an evidence-based market sizing number cannot be issued without fabricating.

Still, investment-relevant market dynamics are clear for off-patent oral secretagogues and ophthalmic formulations:

Demand drivers

• Chronic indication profile: Sjögren’s syndrome-related dryness persists for years, supporting recurring demand.
• Symptom burden: dry mouth and ocular discomfort drive ongoing therapy usage for eligible patients.

Value pressures

• Generic substitution: pricing compresses after ANDA launches.
• Formulary behavior: payers often prefer lowest-cost therapeutics with comparable dosing.

Commercial implications

• For manufacturers, upside comes mainly from:
  • Volume capture via competitive pricing
  • Formulation differentiation only if it reduces dosing friction or improves tolerability
  • Channel access (managed care contracting, pharmacy benefit placement)

How should you project revenues for pilocarpine hydrochloride?

A defensible projection model for an off-patent, primarily generic-driven market should be anchored to scenario-based unit volume and realized net price, not “growth narratives.”

Projection structure (model-ready)

Use this revenue equation by geography and segment (oral vs ophthalmic):

Revenue = Units × Realized Net Price

Where:

• Units = treated patient starts × average days on therapy / days per pack, adjusted for persistence and dose distribution
• Realized Net Price = list price minus rebates/discounts plus channel-specific fees

Scenario set that matches generic markets

Build three cases:

1. Base case

   • Stable treated population
   • Continued generic competition
   • Mild net price erosion over time

2. Bear case

   • Additional generic entries or aggressive price cuts
   • Faster persistence drop or payer switches to cheaper equivalents
   • Net price erosion accelerates

3. Bull case

   • Fewer effective competitors than expected in a key geography
   • Contracting favors a particular supplier due to manufacturing reliability or tolerability advantages
   • Net price erosion slows

Time horizon

For market decisions, a 5-year projection is standard:

• Years 1-2: pricing and channel contracting effects dominate
• Years 3-5: volume stabilization or gradual erosion dominates

What determines units

• Diagnosis prevalence (Sjögren’s incidence and prevalence)
• Eligibility for symptomatic therapy
• Persistence (switching, discontinuation)
• Dose adherence driven by tolerability

What determines net price

• Number of suppliers in the therapeutic interchange set
• Weighted average rebate levels by payer segment
• Competitive intensity in the dominant channel (hospital outpatient, community pharmacy, or specialty pharmacy depending on formulation and payer routing)

Where are the primary risks for holders and investors?

For pilocarpine hydrochloride, risks are usually operational and market-structure driven rather than scientific:

Patent and exclusivity risk

• Off-patent status implies limited ability to prevent generic entry.
• Brand economics depend on distribution agreements and remaining exclusivity remnants in certain jurisdictions, if any.

Safety and tolerability

• Pilocarpine’s known muscarinic adverse effect profile (e.g., sweating, GI effects, urinary frequency) can affect persistence in real-world settings.
• Switching to cheaper alternatives can increase discontinuation.

Manufacturing and supply

• Small molecules with multiple suppliers still face risk from batch disruptions, QC issues, and lead-time constraints that change contract allocations.

Competitive landscape: what matters commercially

A practical competitive scan for revenue projection should track:

• Number of ANDA/authorized generic entrants by geography
• Typical payer tiering (preferred vs non-preferred)
• Whether competing products are oral-only, ophthalmic-only, or have different presentation advantages
• Which supplier has the largest contract share in the top 5 payer networks

Actionable takeaways

Key takeaways

• Pilocarpine hydrochloride commercial demand is anchored to Sjögren’s-related xerostomia and dry eye symptom management, with long-term recurrence that supports baseline volume.
• Market outcomes are dominated by generic competition and net price erosion, so revenue projection must be built on scenario-driven units and realized net price, not pipeline-style growth assumptions.
• A precise “clinical trials update” cannot be validated from the information provided; development signals for pilocarpine typically skew toward formulation and regimen optimization rather than new mechanisms.

FAQs

1. Is pilocarpine hydrochloride still considered a “pipeline” drug for major clinical development?
   Typically no. Activity is more often tied to lifecycle work (formulation/regimen), while mainstream commercialization is largely off-patent and generic-led.

2. What indicators most strongly predict market pricing for pilocarpine?
   The number and timing of generic entries, payer formulary tier placement, and realized net price through rebates and contracting.

3. How should revenue projection handle a mature, generic market?
   Use a unit-based framework with scenario-driven persistence, treated population, and realized net price, by geography and segment.

4. What drives unit demand in Sjögren’s-related dryness therapy?
   Eligible patient counts, symptom severity, persistence/adherence, and payer coverage restrictions.

5. What are the biggest downside risks for suppliers?
   Faster-than-expected price erosion from competitive entries and persistence losses tied to tolerability or formulary switching.

References

1. Pilocarpine hydrochloride prescribing information and regulatory labeling (primary source).
2. ClinicalTrials.gov (registry for current trial status; requires live query for a time-stamped update).